This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 05
  • /
  • Revlimid (Celgene) prolongs disease control for Mu...
Drug news

Revlimid (Celgene) prolongs disease control for Multiple Myeloma patients

Read time: 1 mins
Last updated:18th May 2012
Published:18th May 2012
Source: Pharmawand
Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with Revlimid (lenalidomide), from Celgene, following a stem cell transplant. A Phase III study, co-authored by Richard Maziarz, M.D., of the OHSU Knight Cancer Institute, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy. It was conducted at 47 medical centers and involved 568 patients and the data were supported by similar Phase III studies reported from France and Italy reported in the same issue of the New England Journal of Medicine. See: "Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma." Philip L. McCarthy et al. N Engl J Med 2012; 366:1770-1781May 10, 2012

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.